Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients

Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients

BackgroundImatinib is the most widely used tyrosine kinase inhibitor (TKI) in patients with newly diagnosed chronic-phase chronic myeloid leukemia(CML-CP). However, failure to achieve optimal response after imatinib administration, and subsequent switch to second-generation TKI therapy results in po...

Descrición completa

Detalles Bibliográficos
Main Authors: Yuxin Li, Yilin Zhang, Jin Wang, Aili He, Wanggang Zhang, Xingmei Cao, Yinxia Chen, Jie Liu, Pengyu Zhang, Jianli Wang, Wanhong Zhao, Yun Yang, Xin Meng, Sheping Chen, Longjin Zhang, Ting Wang, Xugeng Wang, Xiaorong Ma
Formato: Artigo
Idioma:English
Publicado: Frontiers Media S.A. 2024-06-01
Series:Frontiers in Oncology
Subjects:
chronic phase chronic myeloid leukemia
imatinib
prognostic model
nomogram
Sokal score
Euro score
Acceso en liña:https://www.frontiersin.org/articles/10.3389/fonc.2024.1418417/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1418417/full

Títulos similares